ImmuMap wins tender and announce research partnership with Ardigen
Today, ImmuMap, a state-of-the-art flow cytometry CRO, and Ardigen, a leading AI and bioinformatics partner for drug developers, announce a research partnership. Ardigen has obtained a grant in the EU-based European Regional Development Fund under the Intelligent Development Program and outsourced selected experimental work. For selection of the best possible candidate a tender has been run, which ImmuMap won in front of several other providers.
The scope of the collaboration between ImmuMap and Ardigen will revolve around the identification of T-cell receptors (TCRs) reactive towards tumor-associated neoantigens. We will run ELISpot assays (enzyme-linked immunosorbent assay), next-generation sequencing (NGS), MHC multimer staining and sorting as well as 10x Genomics Single Cell Immune Profiling.
“We are excited to partner with ImmuMap on this project. The data collected with planned experiments will feed Ardigen’s AI technology development and further expand its capabilities of accelerating TCR-based therapy discovery and development” says Agnieszka Blum, Director of Immunology Unit at Ardigen.
Ardigen is harnessing advanced Artificial Intelligence methods for novel precision medicine. The company accelerates therapy development by designing immunity, decoding microbiome, analysing biomedical images and providing digital drug discovery services. Ardigen’s team is rooted in biology and holds deep expertise in bioinformatics, machine learning, and software engineering. The company’s in-house datasets together with advanced AI platforms empower the development of effective precision therapies.
ArdImmune Vax AI Platform uses sequencing data to generate and prioritize antigen targets of cancer vaccines and T-cell therapies.
TCRact AI Platform is designed to assess target fitness for the use in TCR therapy, suggest TCR sequence improvements, detect potential off-target activity of TCR, and generate novel TCR sequences matching the desired specificity and safety profile.
ImmuMap offers bespoke solutions using immunological cellular analysis based on flow cytometry and enzyme- or fluorescence-linked immunospot (T cell ELISpot assay and T cell fluorospot assay) for immune monitoring and consulting. Staffed by PhD-level scientists and co-founded by immune technology key opinion leader and entrepreneur Dr. Sine Reker Hadrup, our business has extensive scientific and methodological expertise at its core, which allow us to be the perfect partner for our customers.
We have developed several platforms for high-throughput screening and profiling of antigen-specific T cells, including the Deep Profiling assay, providing multilayered characterization of specific T cell populations, and the dCODE™ platform, used for parallel identification and enumeration of 50–1183 different T cell specificities.
The project is co-financed by the European Union from the European Regional Development Fund under the Intelligent Development Program. The project won funding in the call of the National Center for Research and Development: Quick Path.”